Mandate

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.

The share issue was directed to a number of selected Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson and Lorin Arabi.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026